

ASTRAZENECA PLC
Form 6-K
April 26, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of April 2019

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):
82- _____

AstraZeneca PLC

INDEX TO EXHIBITS

1.
Result of AGM

26 April 2019 17:45 BST

Results of Annual General Meeting held on 26 April 2019

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 12 were passed as special resolutions.

| RESOLUTION | VOTES FOR | % OF VOTES CAST | VOTES AGAINST | % OF VOTES CAST | VOTES CAST IN TOTAL | TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL | VOTES WITHHELD |
|--|---------------|-----------------|---------------|-----------------|---------------------|---|----------------|
| 1 To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2018 | 1,002,386,773 | 99.96 | 381,361 | 0.04 | 1,002,768,134 | 76.44% | 2,130,013 |
| 2 To confirm dividends To reappoint | 1,000,878,921 | 99.65 | 3,545,943 | 0.35 | 1,004,424,864 | 76.57% | 474,696 |
| 3 PricewaterhouseCoopers LLP as Auditor To authorise the Directors | 1,003,208,151 | 99.90 | 1,002,311 | 0.10 | 1,004,210,462 | 76.55% | 688,850 |
| 4 to agree the remuneration of the Auditor | 1,002,479,345 | 99.82 | 1,794,309 | 0.18 | 1,004,273,654 | 76.56% | 625,255 |
| 5a To re-elect Leif Johansson as a Director | 998,953,618 | 99.51 | 4,884,897 | 0.49 | 1,003,838,515 | 76.53% | 1,060,758 |
| 5b To re-elect Pascal Soriot as a Director | 1,001,460,120 | 99.73 | 2,740,412 | 0.27 | 1,004,200,532 | 76.55% | 699,226 |
| 5c To re-elect Marc Dunoyer as a Director | 997,205,236 | 99.31 | 6,915,112 | 0.69 | 1,004,120,348 | 76.55% | 775,679 |
| 5d To re-elect Geneviève Berger as a Director | 993,018,194 | 99.77 | 2,314,964 | 0.23 | 995,333,158 | 75.88% | 9,563,029 |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | | | | | |
|----|--|---------------|-------|-------------|-------|---------------|--------|------------|
| 5e | To re-elect Philip Broadley as a Director | 995,659,475 | 99.16 | 8,475,542 | 0.84 | 1,004,135,017 | 76.55% | 761,114 |
| 5f | To re-elect Graham Chipchase as a Director | 958,824,389 | 97.22 | 27,400,052 | 2.78 | 986,224,441 | 75.18% | 18,671,390 |
| 5g | To re-elect Deborah DiSanzo as a Director | 1,001,808,208 | 99.77 | 2,336,040 | 0.23 | 1,004,144,248 | 76.55% | 751,639 |
| 5h | To re-elect Sheri McCoy as a Director | 1,000,164,666 | 99.60 | 3,984,489 | 0.40 | 1,004,149,155 | 76.55% | 746,732 |
| 5i | To elect Tony Mok as a Director | 1,003,431,827 | 99.93 | 699,122 | 0.07 | 1,004,130,949 | 76.55% | 764,625 |
| 5j | To re-elect Nazneen Rahman as a Director | 1,001,687,441 | 99.76 | 2,413,171 | 0.24 | 1,004,100,612 | 76.55% | 795,505 |
| 5k | To re-elect Marcus Wallenberg as a Director | 908,178,624 | 90.44 | 96,025,641 | 9.56 | 1,004,204,265 | 76.55% | 691,663 |
| 6 | To approve the Annual Report on Remuneration for the year ended 31 December 2018 | 947,606,599 | 95.86 | 40,895,170 | 4.14 | 988,501,769 | 75.36% | 16,392,056 |
| 7 | To authorise limited political donations | 977,701,447 | 97.87 | 21,290,398 | 2.13 | 998,991,845 | 76.16% | 5,895,452 |
| 8 | To authorise the Directors to allot shares | 877,861,679 | 87.43 | 126,178,566 | 12.57 | 1,004,040,245 | 76.54% | 853,485 |
| 9 | To authorise the Directors to disapply pre-emption rights | 990,106,053 | 98.92 | 10,841,253 | 1.08 | 1,000,947,306 | 76.31% | 3,944,848 |
| 10 | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments | 979,272,055 | 97.83 | 21,681,201 | 2.17 | 1,000,953,256 | 76.31% | 3,939,912 |
| 11 | To authorise the Company to purchase its own shares | 994,069,976 | 99.04 | 9,657,377 | 0.96 | 1,003,727,353 | 76.52% | 1,164,722 |
| 12 | To reduce the notice period for general meetings | 905,789,402 | 90.67 | 93,205,859 | 9.33 | 998,995,261 | 76.16% | 5,902,125 |

Issued capital

As at 24 April 2019, the number of issued shares of the Company was 1,311,759,192 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations

Gonzalo Viña

UK/Global

+44 203 749 5916

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | |
|-------------------------|-----------|------------------|
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Matt Kent | UK/Global | +44 203 749 5906 |
| Jennifer Hursit | UK/Global | +44 203 749 5762 |
| Christina M Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele Meixell | US | +1 302 885 2677 |

Investor Relations

| | | |
|---------------------|--|------------------|
| Thomas Kudsk Larsen | | +44 203 749 5712 |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Christer Gruvris | BioPharma - Cardiovascular; Metabolism | +44 203 749 5711 |
| Nick Stone | BioPharma - Respiratory; Renal | +44 203 749 5716 |
| Josie Afolabi | Other | +44 203 749 5631 |
| Craig Marks | Finance; Fixed Income | +44 7881 615 764 |
| Jennifer Kretzmann | Retail Investors; Corporate Access | +44 203 749 5824 |
| US toll-free | | +1 866 381 72 77 |

Adrian Kemp
Company Secretary
AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 26 April 2019

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary